Page 2 - Chris Witowski News Today

/PRNewswire/ -- Psilera Inc. ("Psilera"), a biopharmaceutical company optimizing next-generation mental health treatments, announces the patent approval of...

In-depth analysis and perspectives on the issues, people and ideas that define Florida. Statewide coverage of top economic sectors and industries.

In-depth analysis and perspectives on the issues, people and ideas that define Florida. Statewide coverage of top economic sectors and industries.

/PRNewswire/ -- Psilera, Inc. ("Psilera") has named Daniel N. Santiago, Ph.D. as the Director and Head of their Computational Chemistry Department. Dr....

Tampa, Fla. (PRWEB) December 07, 2021 -- Psilera Inc. (“Psilera”), a Florida-based biotechnology company developing non-hallucinogenic derivatives of

The company issued approximately 4.3 million shares to private buyers at a cost of $0.57 per share. Psilera has developed a patent-pending DMT transdermal patch to be assessed in a Phase 1b clinical trial with an investigational new drug (IND) filing with the FDA before the end of the year. Earlier this year, Psilera received DEA approval to research DMT, psilocybin and psilocin. Innovative delivery methods combined with DMT’s short duration of action could lead to a revolutionary new li...

Psilera Expands Team to Include World-Class Researchers and Industry Leaders to Bolster Clinical Psychedelic Pipeline Share Article TAMPA, Fla. (PRWEB) May 11, 2021 Psilera Bioscience (“Psilera”), a Florida-based biotechnology company specializing in the clinical development of psychedelics and analogues is pleased to announce the latest additions to its roster of talent. All bring unique insight to strengthen company leadershi...

Psilera Bioscience Obtains DEA Approval to Conduct Cutting Edge Psychedelics Research Share Article The Drug Enforcement Administration green lights Psilera’s mission to study new DMT and psilocybin treatments for central nervous system disorders We are focused on novel delivery mechanisms to harness neurological benefits while making these treatments more accessible to patients in need. TAMPA, Fla. (PRWEB) February 25, 2021 Psil...

Psilera Bioscience Launches State-of-the-Art Computational Research of Psychedelic-Inspired Compound Library Share Article Psilera is assessing serotonin receptor activation of psychedelic drugs and novel analogues to accelerate and further validate its drug pipeline Serotonin receptor 5-HT2A (purple) crystal structure with example compound (blue ball and stick structure). This translational research is one of many ways that we are raising the bar for the development of psychedelic-based medici...